drugset / Trial / NCT05518071

FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1

NCT05518071 ↗

Phase 2 Completed 20 enrolled Leiden University Medical Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Pancreas as well as Cholangiocarcinoma have a dismal prognosis at time of diagnosis, due to late onset of clinical symptoms, patients present with advance disease. Complete surgical resection is the only potential curative treatment, however only a small percentage is eligible for upfront total surgical resection due to extension into anatomical related important vascular structures. Neoadjuvant chemo(radio)therapy has become the standard treatment modality for non-primary resectable disease (borderline resectable and locally advanced pancreatic cancer (LAPC)), where subsequent downstaging can make identification of the primary tumor more challenging during surgery. Near-infrared (NIR) fluorescence imaging can aid surgeons by providing real-time visualization of tumors, suspect lymph nodes and vital structures during surgery. Additional intra-operative feedback could possibly reduce the frequency of positive resection margins and increase complete removal of locally spread tumor and involved lymph nodes and could thereby improve patient outcomes as well as overall survival. cRGD-ZW800-1 is a targeted NIR-fluorophore, with specific binding capacity for integrins (αvβ3, αvβ5, αvβ6) which are overexpressed on tumor cells and tumor-associated vascular endothelium associated with neoangiogenesis.

Timeline

Start
2022-11-09
Primary completion
2024-05-23
Completion
2024-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject cRGD-ZW800-1 Diagnostic / imaging agent 0.025 mg/kg Intravenous
Subject cRGD-ZW800-1 Diagnostic / imaging agent 0.05 mg/kg Intravenous